Cicada Innovations

Location

Sydney, Australia

Total investments

21

Average round size

2M

Portfolio companies

20

Rounds per year

0.91

Lead investments

8

Follow on index

0.05

Exits

2

Stages of investment
Seed
Areas of investment
BiotechnologySoftwareAnalyticsHealth CareHealth DiagnosticsEnterprise SoftwareMedical DeviceMedicalPharmaceuticalElectronics

Summary

Cicada Innovations is the famous Corporate Investor, which was founded in 2000. The company was established in Australia. The main department of described Corporate Investor is located in the Sydney.

The higher amount of exits for fund were in 2018. When the investment is from Cicada Innovations the average startup value is 10-50 millions dollars. This Cicada Innovations works on 20 percentage points less the average amount of lead investments comparing to the other organizations. The fund is constantly included in 2-6 investment rounds annually. Considering the real fund results, this Corporate Investor is 16 percentage points more often commits exit comparing to other organizations. The important activity for fund was in 2015. The usual things for fund are deals in the range of 1 - 5 millions dollars.

The typical case for the fund is to invest in rounds with 2-3 participants. Despite the Cicada Innovations, startups are often financed by muru-D, Valar Ventures, UBS. The meaningful sponsors for the fund in investment in the same round are Blackbird Ventures (Australia), ZhenFund, Wellcome Trust. In the next rounds fund is usually obtained by Blackbird Ventures (Australia), Y Combinator, Qualcomm Ventures.

Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Clarity Pharmaceuticals, Clarity Pharmaceuticals, Propeller Aero. Among the most popular fund investment industries, there are Travel, Robotics. The fund has no specific favorite in a number of founders of portfolio startups. When startup sums 4 or 5+ of the founder, the probability for it to get the investment is little. For fund there is a match between the country of its foundation and the country of its the most frequent investments - Australia.

Show more

Investor highlights

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
21
Lead investments
8
Exits
2
Rounds per year
0.91
Follow on index
0.05
Investments by industry
  • Health Care (7)
  • Software (4)
  • Enterprise Software (4)
  • Medical (4)
  • Biotechnology (4)
  • Show 45 more
Investments by region
  • Australia (18)
  • United States (3)
Peak activity year
2015

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
8
Avg. valuation at time of investment
9M
Group Appearance index
0.43
Avg. company exit year
11
Avg. multiplicator
8.71

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Beyond 700 14 Oct 2018 Biotechnology, Health Care Seed 0 Australia, Sydney, New South Wales
Elastagen 07 Jan 2016 Medical Device, Medical, Clinical Trials Early Stage Venture 9M New South Wales, Sydney, Australia
Rezerv, Inc. 07 Jun 2018 Mobile Apps, Travel, Sharing Economy, Parking Seed 25K United States, California, Los Angeles

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.